Registry for patients with advanced metastatic colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to evaluate the treatment landscape and clinical outcomes of patients with metastatic colorectal cancer (mCRC) who have received at least two lines of therapy. It will collect data from multiple oncologic centers in Austria, focusing on patients in the third line of therapy and beyond. Information will be gathered from existing medical charts, including treatment history, survival data, and tumor progression. Additionally, imaging studies and tumor tissue samples will be stored for future research, while maintaining patient confidentiality throughout the process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients ≥ 18 years with tissue-based diagnosis of mCRC
* ≥ 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (in case of RAS/BRAF wildtype), anti-PD1- therapy (in case of MSI/MMRd) . (Exception: Patients who have received mFOLFOXIRI +/- anti-VEGF or anti- EGFR- 1L therapy or patients with ineligibility to receive 5-FU, oxaliplatin or irinotecan can be included after 1st line.)

Exclusion Criteria:

* Due to the non-interventional design of this registry, there are no specific exclusion criteria

Where it's running

• Ordensklinikum Linz, BHS - Interne I
  Linz, Austria Recruiting
• KUK Linz - Med Campus III.: Univ.-Klinik für Hämatologie und Internistische Onkologie
  Linz, Austria Recruiting
• LKH Feldkirch: Innere Medizin II/ Interne E (Hämatologie und Onkologie)
  Rankweil, Austria Recruiting
• Department of Internal Medicine III, Paracelsus Medical University Salzburg
  Salzburg, Austria Recruiting
• Klinikum Steyr: Innere Medizin II: Onkologie, Gastroenterologie, Angiologie
  Steyr, Austria Recruiting
• Klinikum Wels: Abteilung für Innere Medizin IV
  Wels, Austria Recruiting

Study contacts

• Study coordinator: Daniela Wolkersdorfer, Dr.
• Email: office@agmt.at
• Phone: +436626404412

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Continuing cetuximab after first progression for metastatic colorectal cancer

  This study will test whether keeping cetuximab while switching the chemotherapy backbone helps adults with RAS/BRAF wild‑type metastatic colorectal cancer whose disease progressed after first‑line anti‑EGFR therapy.

  Recruiting Phase 3 University of Campania Luigi Vanvitelli · Ancona and 40 other locations · NCT07389265

• µCAN diagnostic to pick the best drugs for metastatic colorectal cancer

  This will test whether the µCAN lab test can identify the best drugs for people with metastatic colorectal cancer who are about to start a new line of treatment.

  Recruiting Oncosyne AS · Lørenskog, Akershus · NCT07171554

• Combining hydroxychloroquine with chemotherapy for advanced colorectal cancer

  This study is testing if adding hydroxychloroquine to standard chemotherapy can help people with advanced colorectal cancer live longer and feel better.

  Recruiting Phase 2 Pavlov First Saint Petersburg State Medical University · Saint Petersburg, Sankt-Peterburg · NCT06949982

• Effects of combined exercise on quality of life for colorectal cancer patients undergoing chemotherapy

  This study tests if an 18-week exercise program can improve the quality of life for colorectal cancer patients who are receiving chemotherapy.

  Recruiting at 4 sites Copenhagen University Hospital, Rigshospitalet · Copenhagen and 3 other locations · NCT06938971

• Testing a new treatment for metastatic colorectal cancer

  This study is testing a new treatment called arfolitixorin for people with metastatic colorectal cancer to see if it works better than the usual therapy.

  Recruiting Phase 1/2 Isofol Medical AB · Berlin and 2 other locations · NCT06922383

• Evaluating Fruquintinib for Metastatic Colorectal Cancer

  This study is testing how well Fruquintinib works for people with metastatic colorectal cancer who have already tried other treatments, to see how it affects their survival and quality of life.

  Recruiting at 42 sites iOMEDICO AG · Biberach, Baden-Wurttemberg and 41 other locations · NCT06787105

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.